Vaccin ASTRA-ZENECA

efficacité sur les Covid grave : confirmée

12.021 vaccinés

11.724 placebos

Hospitalisation (WHO clinical progression score ≥4)		
≤21 days after the first dose	2*	6
>21 days after the first dose and ≤14 days after the second dose	0	5
>14 days after the second dose	0	5
Severe COVID-19 (WHO clinical progression score ≥6)		
≤21 days after the first dose	0	0
>21 days after the first dose and ≤14 days after the second dose	0	1
>14 days after the second dose	0	1

The safety population includes all randomisation … eived at least one dose of vaccine. So… of hospitalisations … cacy if the first symptom or … toff date (Nov 4, 2020). Tw… able for serious adverse eve… orting date was after the c… , W, and Y conjugate vac… on the day o…

Table 5: Hospitalisa… the safety population


Articles

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

09 janvier 2021

LIÈGE université
Département de Médecine Générale
Unité de Recherche
Soins primaires et Santé

Vaccin ASTRA-ZENECA

efficacité sur les Covid grave : confirmée

trop peu de personnes plus âgées : *en attente*

12.021 vaccinés

11.724 placebos

Hospitalisation (WHO clinical progression score ≥4)		
≤21 days after the first dose	2*	6
>21 days after the first dose and ≤14 days after the second dose	0	5
>14 days after the second dose	0	5
Severe COVID-19 (WHO clinical progression score ≥6)		
≤21 days after the first dose	0	0
>21 days after the first dose and ≤14 days after the second dose	0	1
>14 days after the second dose	0	1

The safety population includes all randomisation … eived at least one dose of vaccine. So… of hospitalisations … cacy if the first symptom or … toff date (Nov 4, 2020). Tw… able for serious adverse eve… orting date was after the … , W, and Y … on the day o…

Table 5: Hospitalisa… the safety population


Articles

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

09 janvier 2021

LIÈGE université
Département de Médecine Générale
Unité de Recherche
Soins primaires et Santé

Vaccin ASTRA-ZENECA

Ecosse – 490.000 personnes ayant reçu la 1ère dose du vaccin ASTRA-ZENECA

- 94 % d'hospitalisation

dont beaucoup de personnes âgées

LIÈGE université
Département de Médecine Générale
Unité de Recherche
Soins primaires et Santé

Ecosse du 08/12 au 15/02



News

22 février 2021

Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions

BMJ 2021 ; 372 doi: https://doi.org/10.1136/bmj.n523 (Published 22 February 2021)
Cite this as: *BMJ* 2021;372:n523

ASTRA-ZENECA	PFIZER
490.000 (1ère dose)	**650.000** (1ère dose)
4 semaines après :	
- 94 % d'hospitalisations (*)	**- 85 %** d'hospitalisations (*)
personnes âgées +++	**personnes âgées ++**
(*) : comparativement au reste de la population non vaccinée	

LIÈGE université
Département de Médecine Générale
Unité de Recherche
Soins primaires et Santé